Institutional investors purchased a net $744.4 thousand shares of RGEN during the quarter ended June 2015 and now own 93.92% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
STATE STREET GLOBAL ADVISORS LTD... Bought 65.00 shares of Repligen Corp
CREDIT SUISSE AG Sold 700.00 shares of Repligen Corp